|
iNUDGE: Integration of liquid biopsy based next generation gene sequencing in newly diagnosed NSCLC—A stepped wedge cluster randomized clinical trial.
|
May 29, 2024
|
PC3I Authors Anthony Martella; Dylan G. Scholes; Meagan Hume; Charu Aggarwal; Christopher A. D’Avella; Ramy Sedhom; Peter Gabriel; Katharine Rendle; Justin Bekelman; Leland Boisseau; Melina Marmarelis |
Journal of Clinical Oncology
|
|
Estimating Recurrence Risk in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
|
November 5, 2021
|
PC3I Authors Christopher A. D’Avella |
JAMA Network Open
|
|
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|
December 13, 2021
|
PC3I Authors Christopher A. D’Avella |
Journal of the National Comprehensive Cancer Network
|
|
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study
|
April 8, 2022
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella; Anil Vachani |
JTO Clinical and Research Reports
|
|
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed
|
April 8, 2022
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella |
Clinical Lung Cancer
|
|
Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors
|
August 18, 2022
|
PC3I Authors Christopher A. D’Avella |
JAMA Otolaryngology - Head and Neck Surgery
|
|
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer
|
September 22, 2022
|
PC3I Authors Christopher A. D’Avella |
JAMA Otolaryngology - Head and Neck Surgery
|
|
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System
|
April 19, 2023
|
PC3I Authors Michelle Iocolano; Christopher A. D’Avella; Melina Marmarelis; Charu Aggarwal |
Clinical Lung Cancer
|
|
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
|
May 15, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Melina Marmarelis |
The Oncologist
|
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression
|
October 9, 2023
|
PC3I Authors Michelle Iocolano; Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella |
Clinical Lung Cancer
|
|
The impact of an oncology urgent care center on healthcare utilization
|
February 20, 2024
|
PC3I Authors Christopher A. D’Avella |
JNCI Cancer Spectrum
|
